UDP-Glucuronosyltransferases 1A6 and 1A9 are the Major Isozymes Responsible for the 7-O-Glucuronidation of Esculetin and 4-Methylesculetin in Human Liver Microsomes
暂无分享,去创建一个
Liang Liu | Lijun Zhu | Ying Wang | Zhongqiu Liu | Feifei Luo | Peng Wu | Linlin Lu | S. Zeng | P. Dai | Ming Hu | Lijun J. Zhu
[1] D. Makhija,et al. PP265—Attenuation of aluminium induced neurodegeneration by 4-methylesculetin , 2013 .
[2] Andrew Rowland,et al. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. , 2013, The international journal of biochemistry & cell biology.
[3] K. Saikia,et al. Anticancer activity of esculetin via-modulation of Bcl-2 and NF-κB expression in benzo[a]pyrene induced lung carcinogenesis in mice , 2013 .
[4] K. N. Venugopala,et al. Review on Natural Coumarin Lead Compounds for Their Pharmacological Activity , 2013, BioMed research international.
[5] N. Ashokkumar,et al. Protective effect of esculetin on hyperglycemia-mediated oxidative damage in the hepatic and renal tissues of experimental diabetic rats. , 2013, Biochimie.
[6] E. L. Maistro,et al. Antigenotoxic effect of 4-methylesculetin on mice cells exposed to doxorubicin , 2012 .
[7] D. Hadjipavlou-Litina,et al. Coumarin-based drugs: a patent review (2008 – present) , 2012, Expert opinion on therapeutic patents.
[8] Guangbo Ge,et al. Investigation of UDP‐glucuronosyltransferases (UGTs) Inhibitory Properties of Carvacrol , 2012, Phytotherapy research : PTR.
[9] E. Del Grosso,et al. Identification of the Human UDP-Glucuronosyltransferases Involved in the Glucuronidation of Combretastatin A-4 , 2010, Drug Metabolism and Disposition.
[10] Yan-Yan Zhang,et al. Identification and Characterization of Human UDP-Glucuronosyltransferases Responsible for the In Vitro Glucuronidation of Daphnetin , 2010, Drug Metabolism and Disposition.
[11] S. Kok,et al. Esculetin enhances TRAIL-induced apoptosis through DR5 upregulation in human oral cancer SAS cells. , 2009, Oral oncology.
[12] Yiyi Hu,et al. Chinese herbal medicinal ingredients inhibit secretion of IL-6, IL-8, E-selectin and TXB2 in LPS-induced rat intestinal microvascular endothelial cells , 2009, Immunopharmacology and immunotoxicology.
[13] K. Kang,et al. Protective effect of esculetin against oxidative stress-induced cell damage via scavenging reactive oxygen species , 2008, Acta Pharmacologica Sinica.
[14] Yung-Hyun Choi,et al. Induction of apoptosis by esculetin in human leukemia U937 cells through activation of JNK and ERK. , 2008, Toxicology and applied pharmacology.
[15] V. Tam,et al. Disposition of flavonoids via enteric recycling: determination of the UDP-glucuronosyltransferase isoforms responsible for the metabolism of flavonoids in intact Caco-2 TC7 cells using siRNA. , 2007, Molecular pharmaceutics.
[16] P. Soares-da-Silva,et al. Human Metabolism of Nebicapone (BIA 3-202), a Novel Catechol-O-Methyltransferase Inhibitor: Characterization of in Vitro Glucuronidation , 2006, Drug Metabolism and Disposition.
[17] V. Tam,et al. Disposition of Flavonoids via Enteric Recycling: Structural Effects and Lack of Correlations between in Vitro and in Situ Metabolic Properties , 2006, Drug Metabolism and Disposition.
[18] J. Miners,et al. SELECTIVITY OF SUBSTRATE (TRIFLUOPERAZINE) AND INHIBITOR (AMITRIPTYLINE, ANDROSTERONE, CANRENOIC ACID, HECOGENIN, PHENYLBUTAZONE, QUINIDINE, QUININE, AND SULFINPYRAZONE) “PROBES” FOR HUMAN UDP-GLUCURONOSYLTRANSFERASES , 2006, Drug Metabolism and Disposition.
[19] K. Leung,et al. Immunomodulatory effects of esculetin (6,7-dihydroxycoumarin) on murine lymphocytes and peritoneal macrophages. , 2005, Cellular & molecular immunology.
[20] Tony K L Kiang,et al. UDP-glucuronosyltransferases and clinical drug-drug interactions. , 2005, Pharmacology & therapeutics.
[21] T. Kaneko,et al. Suppression of lipid hydroperoxide-induced oxidative damage to cellular DNA by esculetin. , 2003, Biological & pharmaceutical bulletin.
[22] J. Magdalou,et al. Glucuronidation of catechols by human hepatic, gastric, and intestinal microsomal UDP-glucuronosyltransferases (UGT) and recombinant UGT1A6, UGT1A9, and UGT2B7. , 2003, Archives of biochemistry and biophysics.
[23] T. Tseng,et al. Inhibitory effect of esculetin on oxidative damage induced by t-butyl hydroperoxide in rat liver , 2000, Archives of Toxicology.
[24] B. Lake,et al. Coumarin metabolism, toxicity and carcinogenicity: relevance for human risk assessment. , 1999, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[25] Y. Okada,et al. Search for naturally occurring substances to prevent the complications of diabetes. II. Inhibitory effect of coumarin and flavonoid derivatives on bovine lens aldose reductase and rabbit platelet aggregation. , 1995, Chemical & pharmaceutical bulletin.
[26] J. Hoult,et al. Inhibitory activity of a series of coumarins on leukocyte eicosanoid generation , 1994, Agents and Actions.
[27] B. Halliwell,et al. Interactions of a series of coumarins with reactive oxygen species. Scavenging of superoxide, hypochlorous acid and hydroxyl radicals. , 1992, Biochemical pharmacology.
[28] E. Ragazzi,et al. Anti-inflammatory and peripheral analgesic activity of esculetin in vivo. , 1988, Pharmacological research communications.
[29] Kiyoshi Yamaoka,et al. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations , 1978, Journal of Pharmacokinetics and Biopharmaceutics.
[30] D. Egan,et al. The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds. , 1990, Drug metabolism reviews.